U.S. FDA issues two observations to Cipla arm InvaGen’s U.S. facility
- Business
- February 10, 2026
- No Comment
- 5
The observations followed a pre-approval inspection (PAI) by the regulator at InvaGen’s manufacturing facility in Hauppauge, Long Island, New York
